Mycosis Fungoides Treatment Market Report 2026

The mycosis fungoides treatment market size has grown strongly in recent years. It will grow from $1.03 billion in 2025 to $1.1 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to limited treatment options, increasing prevalence of cutaneous t-cell lymphoma, reliance on radiation therapy, delayed diagnosis rates, dependence on topical steroids.

The mycosis fungoides treatment market size is expected to see strong growth in the next few years. It will grow to $1.37 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to growth in targeted therapies, rising use of immunotherapy, expansion of dermatology oncology centers, improved diagnostic capabilities, increased investment in rare cancer research. Major trends in the forecast period include growing adoption of combination therapy approaches, increasing use of topical steroids for early-stage management, rising preference for targeted therapies and immunotherapy, expansion of photodynamic and radiation therapy options, higher demand for specialized dermatology and oncology clinics.

The increasing incidence of lymphoma cancer is expected to propel the growth of the mycosis fungoides treatment market going forward. Lymphoma is a cancer of the lymphatic system, which includes the lymph nodes, spleen, thymus gland, and bone marrow. The rise in lymphoma incidence is driven by a combination of factors such as environmental exposures, higher rates of viral infections, an aging population, and lifestyle-related influences. Treatments for mycosis fungoides, including topical corticosteroids, phototherapy, and systemic therapies, are used to manage cutaneous T-cell lymphomas by controlling skin lesions, alleviating symptoms, and slowing disease progression. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization, non-Hodgkin lymphoma (NHL) was among the most common cancers in the United States, representing about 4% of all cancer cases. It was estimated that approximately 80,620 individuals (44,590 males and 36,030 females) would be diagnosed with NHL, and around 20,140 deaths (11,780 males and 8,360 females) would occur in 2024. Therefore, the rising incidence of lymphoma cancer is driving the growth of the mycosis fungoides treatment market.

Major companies operating in the mycosis fungoides treatment market are focusing on developing advanced therapeutic approaches, such as targeted immunotherapy, to improve treatment effectiveness and enhance patient quality of life. Targeted immunotherapy selectively attacks malignant T-cells and regulatory T-cells while sparing healthy tissues, enabling faster disease control with fewer adverse effects. For instance, in August 2024, Citius Pharmaceuticals, a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved LYMPHIR (denileukin diftitox-cxdl), an IL-2 receptor-targeted immunotherapy. The treatment is approved for adults with relapsed or refractory cutaneous T-cell lymphoma, including mycosis fungoides, following at least one prior systemic therapy. LYMPHIR employs a novel mechanism of action that directly eliminates malignant T-cells and reduces regulatory T-cells to enhance immune response. Clinical data showed a 36% objective response rate with a rapid median time to response of 1.4 months, along with skin disease reduction in 84% of patients and improvement in pruritus without cumulative toxicity. This therapy offers a valuable systemic option for Stage I-III patients and addresses unmet needs in populations with limited treatment choices.

In October 2023, Shorla Oncology, an Ireland-based pharmaceutical company, acquired Jylamvo from Therakind for an undisclosed amount. Through this acquisition, Shorla aims to introduce Jylamvo to the US market, where it has received approval for the treatment of conditions such as acute lymphoblastic leukemia and mycosis fungoides. Therakind Limited is a UK-based pharmaceutical company that specializes in the development of niche medicines.

Major companies operating in the mycosis fungoides treatment market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Tocris Bioscience, Viatris Inc., Astellas Pharma Inc., Daiichi Sankyo Company, Takeda Pharmaceutical Company Limited, Bausch Health, Eisai Co. Ltd., Horizon Therapeutics plc, Varian Medical Systems, Kyowa Kirin Co. Ltd., Seattle Genetics Inc., Azurity Pharmaceuticals Inc., Innate Pharma S.A., Helsinn Therapeutics, Jubilant Cadista Pharmaceuticals Inc., Elorac Inc., Soligenix Inc., Ceptaris Therapeutics Inc.

North America was the largest region in the mycosis fungoides treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mycosis fungoides treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mycosis fungoides treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on pharmaceutical ingredients and oncology formulations have increased production and import costs in the mycosis fungoides treatment market, slowing access to advanced therapies such as immunotherapy and topical nitrogen mustard in regions reliant on imports. Hospitals and specialty clinics in Asia-Pacific and Latin America are the most affected due to higher dependency on foreign supplies. However, tariffs have also stimulated local drug manufacturing and encouraged regional players to develop cost-effective formulations, strengthening long-term supply resilience.

The mycosis fungoides treatment market research report is one of a series of new reports that provides mycosis fungoides treatment market statistics, including mycosis fungoides treatment industry global market size, regional shares, competitors with a mycosis fungoides treatment market share, detailed mycosis fungoides treatment market segments, market trends and opportunities, and any further data you may need to thrive in the mycosis fungoides treatment industry. This mycosis fungoides treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mycosis fungoides treatment refers to the use of various therapies, medications, and procedures to manage and relieve the symptoms of cutaneous T-cell lymphoma, a rare type of non-Hodgkin lymphoma that primarily affects the skin. Treatment usually involves a combination of approaches, including topical therapies and systemic treatments such as immunotherapy, depending on the disease stage and severity.

The main types of mycosis fungoides treatment include topical steroids and mechlorethamine. Topical steroids are applied directly to the skin to reduce inflammation and irritation. Additional treatment options include photodynamic therapy, radiation therapy, targeted therapy, and chemotherapy, which are utilized by end users such as hospitals, private clinics, and specialty clinics.

The mycosis fungoides treatment market consists of revenues earned by entities by providing services, such as phototherapy, dermatological care, and specialized therapies. The market value includes the value of related services provided by the treatment creators or included within the treatment offering. The mycosis fungoides treatment market also includes sales of oral retinoids, interferons, monoclonal antibodies, and nitrogen mustard. Values in this market are ‘factory gate’ values, that is, the value of treatments sold by the manufacturers or creators of the treatments, whether to other entities (including downstream healthcare providers and pharmacies) or directly to end customers. The value of treatments in this market includes related services sold by the creators of the treatments.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.